HBI 0201-ESO TCRT
Phase 2Cell therapy
HBI 0201-ESO TCRT is one of 20 biologic programs targeting Metastatic Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Metastatic Cancer
#DrugCompanyPhaseTrials
1Avastin
RocheApproved
Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Proleukin
IIovance Biotherapeutics, Inc.
Phase 2
Yervoy
Bristol-Myers SquibbPhase 2
Lenvima
EisaiPhase 2
Talzenna
PfizerPhase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Zejula
GGlaxo Dba Glaxosmithkline
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HBI 0201-ESO TCRT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- HHadassah Medical Organization